Kerlone (Betaxolol Hydrochloride)

Betaxolol selectively blocks β1‑adrenergic receptors in the heart, preventing catecholamines from stimulating these receptors. This leads to a slower heart rate, reduced contractile force, and lower renin release from the kidneys, collectively decreasing cardiac output and systemic vascular resistance, which lowers arterial blood pressure and myocardial oxygen demand.

The dosage of Kerlone is individualized by the prescribing clinician based on the patient’s blood pressure, heart rate, renal function, and overall clinical condition. The prescriber determines the appropriate strength, frequency, and titration schedule, and patients should follow the written prescription without alteration.

The safety of betaxolol hydrochloride during pregnancy and lactation has not been definitively established, and it is classified as pregnancy category unknown. Healthcare providers should weigh potential benefits against possible risks, and it is generally recommended to avoid use unless clearly needed. Breastfeeding mothers should consult their physician before use.

To request Kerlone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, and will verify trade or institutional credentials. The sales team then provides pricing, availability, shipping details (including any cold‑chain requirements), and assists with import documentation.

Compared with non‑selective β‑blockers, betaxolol offers greater β1 selectivity, which may reduce the risk of bronchospasm in patients with mild respiratory disease. Relative to calcium channel blockers, it primarily lowers heart rate rather than causing vasodilation. Choice of therapy depends on individual patient profile, comorbidities, and physician judgment.

Kerlone should be stored below 25 °C in a dry environment. Keep the tablets in the original container, protect them from moisture and direct sunlight, and ensure the packaging remains sealed until use. Do not refrigerate or freeze the product, and keep it out of reach of children.

Kerlone is taken orally, usually with or without food, as directed by the prescribing physician. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescriber advises otherwise. Consistent timing each day helps maintain stable blood levels.

The most serious adverse events include severe bradycardia, heart block, marked hypotension, and allergic reactions such as anaphylaxis. Patients experiencing faintness, very slow pulse, chest pain, or signs of an allergic response should seek immediate medical attention. Regular monitoring can help detect these risks early.

Kerlone is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block, cardiogenic shock, or overt heart failure. It should also be avoided in individuals with known hypersensitivity to betaxolol or any component of the formulation. Clinicians must assess each patient’s medical history before initiating therapy.